Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring.
Oncologist
; 2024 Jul 31.
Article
in En
| MEDLINE
| ID: mdl-39083323
ABSTRACT
BACKGROUND:
Patients with breast cancer exhibit heterogeneity in the expression of the human epithelial growth factor receptor 2 (HER2). Clinically, re-biopsying recurrent or metastatic lesions presents substantial challenges. This study aimed to evaluate the efficacy of HER2-targeted PET/CT imaging in identifying HER2 expression in breast cancer lesions and monitoring therapeutic responses. PATIENTS ANDMETHODS:
This exploratory analysis used data from a prospective study that included adult patients with breast cancer who underwent both Al18F-NOTA-HER2-BCH and 18F-FDG PET/CT imaging at Beijing Cancer Hospital between June 2020 and July 2023 (NCT04547309).RESULTS:
Fifty-nine participants, with a median age of 55 years, were analyzed. Lesions imaged with HER2-targeted PET/CT before anti-HER2 therapy exhibited higher SUVmax values than after therapy in HER2 immunohistochemistry (IHC) 3â +â lesions (19.9, 95% CI 15.7-25.3 vs 9.8, 95% CI 5.6-14.7; Pâ =â .006). A significant positive correlation was observed between SUVmax on HER2-targeted PET/CT and IHC before therapy (Pâ =â .034), with higher SUVmax values noted in lesions with positive HER2 pathology compared to those with negative HER2 status (17.9â ±â 13.2 vs 1.1â ±â 0.3; Pâ =â .007). HER2 expression heterogeneity was confirmed both between primary and metastatic lesions (22.9%) and among different metastatic sites (26.7%) as assessed by HER2-targeted PET/CT. A superior therapeutic response correlated with higher pretreatment SUVmax values. The HER2-targeted PET/CT procedure was well-tolerated by all patients.CONCLUSION:
HER2-targeted PET/CT imaging offers a practical, non-invasive, and quantitative approach for assessing HER2 status in breast cancer patients, facilitating the optimization and personalization of therapeutic strategies by oncologists.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Oncologist
Journal subject:
NEOPLASIAS
Year:
2024
Document type:
Article
Country of publication:
United kingdom